- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Control of pruritus pushes pimecrolimus
Washington - "Control of itching is critical to the management of atopic dermatitis in children, and Elidel safely and rapidly controls itching in many cases," said Joseph F. Fowler, Jr., M.D., Clinical Professor of Dermatology at the University of Louisville and one of the investigators in a large, multicenter clinical trial evaluating the safety and efficacy of pimecrolimus 1 percent cream (Elidel, Novartis) for the treatment of mild to moderate atopic dermatitis in children. Previous clinical research had demonstrated that adults with atopic dermatitis can experience relief from pruritus as early as two days following first treatment with pimecrolimus 1 percent cream, but similar research had not been carried out in a pediatric population. Data from this Phase IV pediatric study were analyzed to determine the time to first pruritus improvement during the initial seven days of treatment.
